[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.21660
|
[2] |
DESANTIS C E, MA J M, GAUDET M M, et al. Breast cancer statistics, 2019[J]. CA A Cancer J Clin, 2019, 69(6): 438-451.
doi: 10.3322/caac.21583
|
[3] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040.
|
|
The Society of Breast Cancer China Anti-Cancer Association. Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2021 edition)[J]. China Oncol, 2021, 31(10): 954-1040.
|
[4] |
HUERTA-REYES M, MAYA-NÚÑEZ G, PÉREZ-SOLIS M A, et al. Treatment of breast cancer with gonadotropin-releasing hormone analogs[J]. Front Oncol, 2019, 9: 943.
doi: 10.3389/fonc.2019.00943
|
[5] |
LU Y S, WONG A, KIM H J. Ovarian function suppression with luteinizing hormone-releasing hormone agonists for the treatment of hormone receptor-positive early breast cancer in premenopausal women[J]. Front Oncol, 2021, 11: 700722.
doi: 10.3389/fonc.2021.700722
|
[6] |
DAVIDSON N E, O'NEILL A M, VUKOV A M, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)[J]. J Clin Oncol, 2005, 23(25): 5973-5982.
doi: 10.1200/JCO.2005.05.551
|
[7] |
FRANCIS P A, PAGANI O, FLEMING G F, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer[J]. N Engl J Med, 2018, 379(2): 122-137.
doi: 10.1056/NEJMoa1803164
|
[8] |
KIM H A, LEE J W, NAM S J, et al. Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(5): 434-443.
|
[9] |
MASUDA N, SAGARA Y, KINOSHITA T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(4): 345-352.
doi: 10.1016/S1470-2045(11)70373-4
|
[10] |
GNANT M, MLINERITSCH B, STOEGER H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian breast and colorectal cancer study group trial 12[J]. Ann Oncol, 2015, 26(2): 313-320.
doi: 10.1093/annonc/mdu544
|
[11] |
PERRONE F, DE LAURENTIIS M, DE PLACIDO S, et al. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial[J]. Eur J Cancer, 2019, 118: 178-186.
doi: 10.1016/j.ejca.2019.05.004
|
[12] |
BELLET M, GRAY K P, FRANCIS P A, et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy[J]. J Clin Oncol, 2016, 34(14): 1584-1593.
doi: 10.1200/JCO.2015.61.2259
|
[13] |
ALLISON K H, HAMMOND M E H, DOWSETT M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update[J]. J Clin Oncol, 2020, 38(12): 1346-1366.
doi: 10.1200/JCO.19.02309
|
[14] |
WOLFF A C, HAMMOND M E H, ALLISON K H, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update[J]. J Clin Oncol, 2018, 36(20): 2105-2122.
|
[15] |
HOSMER JR D W, LEMESHOW S, STURDIVANT R X. Applied logistic regression[M]. John Wiley & Sons, 2013.
|
[16] |
CHOWDHURY M Z I, TURIN T C. Variable selection strategies and its importance in clinical prediction modelling[J]. Fam Med Community Health, 2020, 8(1): e000262.
|